Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.

Learn More
Solutions
Online Inquiry

In Situ Transplantation Brain Tumor Models

The most common brain tumors (e.g., gliomas), generally have a high mortality rate. Despite continuous improvements in surgery, radiotherapy, and chemotherapy techniques, their recurrence rate is high and their prognosis remains poor. The reason for this is the failure to elucidate the process of brain tumor development, especially the difficulty to observe its intracranial growth in real-time during the tumor growth stage. Therefore, Alfa Cytology' animal models of brain tumors, which can be monitored in real-time, are essential for our customers to study the pathogenesis of brain tumors and explore therapeutic approaches.

We provide in situ transplantation model building services for brain tumors

Glioma

Cells labeled with GFP and luciferase gene-labeled dual fluorescent systems have shown great advantages in the study of tumor animal models such as high safety, easy operation, low price, and real-time quantitative monitoring. We used U251 cells and screened a stable transfer cell line after GFP-luciferase gene labeling to establish a non-invasive, real-time monitorable glioma animal model for our customers.

Glioma animal model - Alfa Cytology

Various new ideas and methods for glioma treatment have been put into preclinical and clinical practice applications, but the results are less satisfactory. A large number of experiences with successful animal experiments and poor clinical evaluations indicate that animal models do not reflect the real physiological characteristics of patients' tumors. This is why we have developed such a reliable and stable glioma in situ transplantation model for our customers. This allows you to observe the development of tumors in the brain in real time, non-invasively, and accurately.

Malignant meningioma

Meningioma is one of the most common intracranial tumors, and malignant meningioma is a challenge in meningioma treatment because of its recurrent recurrence after surgery. One of the reasons for the slow progress in basic research on meningioma is the lack of good cellular as well as animal models. Intracranial in situ tumorigenesis, which helps to realize the study of tumor interaction with the surrounding microenvironment, can maximize the simulation of the real situation of tumors in the skull. Therefore, we have established a mouse in situ tumorigenesis model of malignant meningioma for our customers, which can provide you with more options for basic meningioma research.

In situ tumorigenesis model of malignant meningioma - Alfa Cytology

  • We have improved our primary culture method for malignant meningioma by using the differential apposition method, which purifies malignant meningioma cells and reduces the number of mixed fibroblasts.
  • We established a mouse in situ tumorigenesis model along with a mouse subcutaneous transplantation tumor model, compared the pathological characteristics of the tumors formed by the two models, and determined that the tumors formed by the in situ tumorigenesis model did not change their inherent pathological characteristics compared with the subcutaneous transplantation tumorigenesis model.

Alfa Cytology successfully constructed a mouse intracranial tumorigenesis model using primary human malignant meningioma cells and established a glioma animal model using U251 cells and a stable transgenic cell line screened with GFP-luciferase gene labeling. This provides a reliable research model for our customers to study the effect of tumor microenvironment on the occurrence of malignant meningioma, glioma, and other brain tumors, their development, and tumor invasion to surrounding tissues. Please feel free to contact us for customized in situ brain tumor transplant models.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.